Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of DHEA plus aromatase inhibitor in AR-positive metastatic breast cancer
2012-003510-13Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Mar 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dehydroepiandrosterone, anastrozole, letrozole and exemestane in breast cancer (3 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Safety of treatment of the combination of DHEA and an aromatase inhibitor. Started Mar 2013; status: terminated.
02
Drugs
dehydroepiandrosteroneanastrozoleletrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-003510-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003510-13.